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TTC5 is required to prevent apoptosis of acute myeloid
leukemia stem cells
JT Lynch1, TDD Somerville1, GJ Spencer1, X Huang1 and TCP Somervaille*,1
Using a screening strategy, we identified the tetratricopeptide repeat (TPR) motif protein, Tetratricopeptide repeat domain
5 (TTC5, also known as stress responsive activator of p300 or Strap) as required for the survival of human acute myeloid
leukemia (AML) cells. TTC5 is a stress-inducible transcription cofactor known to interact directly with the histone
acetyltransferase EP300 to augment the TP53 response. Knockdown (KD) of TTC5 induced apoptosis of both murine and human
AML cells, with concomitant loss of clonogenic and leukemia-initiating potential; KD of EP300 elicited a similar phenotype.
Consistent with the physical interaction of TTC5 and EP300, the onset of apoptosis following KD of either gene was preceded by
reduced expression of BCL2 and increased expression of pro-apoptotic genes. Forced expression of BCL2 blocked apoptosis
and partially rescued the clonogenic potential of AML cells following TTC5 KD. KD of both genes also led to the accumulation of
MYC, an acetylation target of EP300, and the form of MYC that accumulated exhibited relative hypoacetylation at K148 and K157,
residues targeted by EP300. In view of the ability of excess cellular MYC to sensitize cells to apoptosis, our data suggest a model
whereby TTC5 and EP300 cooperate to prevent excessive accumulation of MYC in AML cells and their sensitization to cell death.
They further reveal a hitherto unappreciated role for TTC5 in leukemic hematopoiesis.
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Acutemyeloid leukemia (AML) is a genetically heterogeneous
clonal disorder characterized by the accumulation of poorly
differentiated myeloid precursor cells in the bone marrow
(BM) and blood.1 Epigenetic dysfunction is central to the
molecular pathology of the disease, as evidenced by the
recurrent mutations in genes coding for proteins that directly
or indirectly regulate the structure and function of chromatin.2
Commonly occurring exemplar mutations in myeloid cancers
include those targeting the gene coding for the histone H3K4
methyltransferase MLL, either by chromosomal translocation
or partial tandem duplication; those inactivating the enzymatic
activities of DNA methyltransferase 3A or the methylcytosine
dioxygenase TET2; or those targeting isocitrate dehydro-
genase 1 or 2, which result in the production by the mutant
enzyme of a neometabolite, 2-hydroxyglutarate, which inhibits
the activities of TET-family proteins and Jumonji-domain
histone demethylases.2 Further understanding of the struc-
ture and function of chromatin in myeloid leukemia cells may
lead to the identification of novel therapeutic targets and
strategies.
In the course of our studies, we performed a lentiviral short
hairpin RNA (shRNA) genetic knockdown screen to identify
regulators of chromatin structure and function required for the
proliferation or survival of humanAML cells (Huang et al, 2013,
manuscript submitted). The screen identified tetratrico-
peptide repeat domain 5 (TTC5; also known as stress
responsive activator of p300, Strap) as required for leukemia
cell survival. TTC5 is a tetratricopeptide repeat (TPR) motif
protein known to have important roles in DNA damage and
heat-shock responses. It was originally discovered in complex
with an EP300-interacting protein called junction mediating
and regulatory protein (JMY), and the histone acetyltransfer-
ase (HAT) EP300 (E1A-binding protein p300; also known as
p300) itself.3 TTC5 augments the interaction of JMY and
EP300, increasing the HAT activity of EP300. This leads to
enhanced TP53 acetylation, stability and transcriptional
activation during the DNA damage response.3 TTC5 is
phosphorylated by ataxia telangiectasia mutated (ATM) at
S203 and checkpoint kinase 2 (CHK2) at S221. These phos-
phorylations promote its stability and nuclear accumulation,
also augmenting TP53 activity and promoting apoptosis in
etoposide-treated cells.4,5 In the heat shock response, TTC5
associates with heat shock factor 1 (HSF1) in a chromatin-
bound complex that includes EP300. The complex is located
at the promoters of heat shock genes and is required to
prevent apoptosis.6 A physical interaction of TTC5 with
Protein Methyltransferase 5 (PRMT5), which arginine methy-
lates TP53, has been reported,7 as has a regulatory role for
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TTC5 in steroid hormone signaling where it acts as a cofactor
for the glucocorticoid and estrogen receptors.8
While TTC5 is ubiquitously expressed, including in hema-
topoietic cells (data not shown), to date there is no information
as to any functional role for TTC5 in normal or leukemic
hematopoiesis. Here, we present evidence demonstrating
a critical role for TTC5 in prevention of apoptosis of human
AML cells.
Results
TTC5 is required to prevent apoptosis of AML cells. To
confirm the preliminary results from our knockdown screen
(data not shown), human THP1 AML cells were infected with
lentiviral vectors targeting TTC5 for KD. THP1 cells exhibit
a t(9;11) translocation, which is the cytogenetic hallmark of
MLL-AF9, a fusion oncogene found in 4–5% of patients with
AML.1 Successfully transduced cells, as indicated by
puromycin drug resistance, were then cultured in semisolid
conditions to assess their clonogenic potential. Untrans-
duced THP1 cells treated with puromycin are killed by drug
within 48 h (data not shown). While control cells that were
infected with a vector expressing a non-targeting hairpin
formed plentiful colonies, cells infected with vectors expres-
sing hairpins targeting TTC5 for KD formed significantly
fewer colonies (Figure 1a). TTC5 KD was confirmed at both
the mRNA and protein levels, and the extent of TTC5 KD
correlated with the observed reduction in clonogenic potential
(Figures 1b and c). To confirm that the phenotype was an on-
target effect of TTC5 KD, we performed repeat experiments
using THP1 cells that stably expressed a version of human
TTC5 that lacked the 30-UTR sequences targeted by KD
constructs #1 and #4 (Figure 1d). A partial (construct #1) or
complete (construct #4) rescue of clonogenic potential was
observed (Figure 1e), providing strong additional evidence
that the observed phenotype was specific for TTC5. The loss
of clonogenic potential following TTC5 KD was in large part
due to induction of apoptosis (Figure 1f), although a modest
but statistically significant G1 arrest with reduction in the
proportion of cells in S phase was also observed (Figure 1g).
Thus, TTC5 is required to prevent apoptosis and maintain the
proliferative and clonogenic potential of human AML cells.
To determine whether TTC5 is required for the leukemia-
initiating potential of human AML cells, we transplanted
control or KD THP1 AML cells into sublethally irradiated
immune-deficientmice. All mice injected with control cells died
of short latency AML, whereas mice injected with TTC5 KD
cells did not succumb to leukemia (Figures 2a and b). There
was no evidence of leukemic engraftment in any of the mice
euthanized at the termination of the experiment (Figure 2b
and data not shown). To determine whether the observed
dependency on TTC5 was specific to the MLL molecular
subtype of AML or amore general feature of myeloid leukemia
cells,TTC5KDwas initiated in additional humanAML cell lines.
Significant loss of clonogenic potential of AML cells was
Figure 1 TTC5 prevents apoptosis of THP1 MLL-AF9 AML cells. THP1 cells were infected with lentiviruses expressing shRNAs targeting TTC5 for KD, or a non-targeting
control shRNA (NTC), with puromycin drug resistance as the selectable marker. Next day, successfully infected cells were drug-selected in puromycin (3mg/ml) for 48 h. Bar
charts show (a) mean±S.E.M. colony forming cell (CFC) frequencies of drug-resistant cells enumerated after 10 days in semisolid culture (n¼ 3); and (b) mean±S.E.M.
TTC5 mRNA levels in KD cells relative to control cells, 72 h after lentiviral infection. Representative western blots show expression of (c) endogenous TTC5 and ACTB in KD
and control cells, 7 days after lentiviral infection or (d) endogenous or ectopically expressed TTC5 in THP1 cell lines stably infected with the indicated vectors. Vertical dashed
line indicates intervening gel lanes excised for clarity of presentation. Bar charts show (e) mean±S.E.M. CFC frequencies in control or KD cells with or without ectopic
expression of human TTC5 (n¼ 3); (f) mean±S.E.M. percentage of apoptotic cells, as determined by annexin V binding, 7 days after lentiviral infection of THP1 cells (n¼ 3)
and (g) mean±S.E.M. percentage of control or KD cells in the indicated phase of the cell cycle (n¼ 5). S.E.M.¼ standard error of the mean; EV¼Empty Vector; TTC5
O/E¼ force-expressed TTC5; * indicates Pp0.05 for comparison of KD versus control conditions, or for the indicated comparisons, using one-way ANOVA and Fisher’s least
significant difference post hoc test for (a), (b), (f) and (g) and an unpaired t-test for (e)
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observed following TTC5 KD in both MLL mutated lines
(MonoMac1 and MV4;11) and lines representative of other
AML molecular subtypes (NB4 and K562) (Figure 2c). There
was also a reduction in the clonogenic potential of TTC5 KD
HL60 cells, although this did not reach statistical significance.
These data demonstrate that TTC5 is required for the
leukemia-initiating potential of human AML cells and that the
requirement for TTC5 is not specific to the MLL mutated
molecular subtype.
To confirm and expand these observations in a separate
species, we performed similar experiments using a mouse
model of human MLL-AF9 leukemia, which faithfully recapi-
tulates many of the clinical and pathological features of the
human disease.9 Three separate lentivirally expressed
shRNAs were used to target murine Ttc5 in murine
MLL-AF9 AML cells, this time with GFP as the selectable
marker. The extent of transcript KD, as determined byQ-PCR,
correlated once more with significant loss of clonogenic
potential (Figures 3a and b). To determine whether the
leukemia stem cell (LSC) compartment of the leukemia clone
was targeted by Ttc5 KD, we performed secondary trans-
plantation of FACS-purified control or Ttc5 KD MLL-AF9 AML
cells 48 h following lentiviral infection.10 As for human THP1
cells, all mice receiving control AML cells died of short latency
disease, whereas mice transplanted with Ttc5 KD AML cells
survived until the termination of the experiment (Figure 3c),
and at autopsy exhibited no evidence of leukemic engraft-
ment, as determined by flow cytometry of bone marrow cells.
By contrast, engraftment of donor GFPþ AML cells in the BM
of leukemic mice was readily confirmed (Figure 3d). These
data confirm that, as for human AML cells, Ttc5 is essential for
murine MLL-AF9 leukemia-initiating cells.
Figure 2 TTC5 is required for the leukemia-initiating potential of AML cells. THP1 human AML cells were infected with lentiviruses expressing shRNAs targeting TTC5 for
KD, or a non-targeting control (NTC) shRNA, with puromycin drug resistance as the selectable marker. (a) Survival curves of sublethally irradiated immune-deficient mice
transplanted with 5000 viable drug resistant control or TTC5 KD THP1 cells (n¼ 5 per cohort). (b) Representative FACS plots show percentage human CD45þ THP1 AML
cells in the BM of recipient mice either at death (NTC) or at termination of the experiment on day 125 (TTC5 KD). (c) Bar chart shows mean±S.E.M. colony-forming cell (CFC)
frequencies of drug-resistant TTC5 KD cells relative to control cells enumerated after 10 days in semisolid culture for the indicated AML cell lines. * Indicates Pp0.05 for
comparison of KD versus control conditions using one-way ANOVA and Fisher’s least significant difference post hoc test
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TTC5 sustains expression of BCL2 in AML cells. To
address the mechanism by which TTC5 KD cells undergo
apoptosis, we determined transcript levels of a panel of
genes coding for proteins that regulate cell death 96 and
120h following lentiviral infection of THP1 AML cells.
Relative to that of ACTB, expression of the anti-apoptotic
gene BCL2 decreased by 450% and expression of pro-
apoptotic genes such as BAK1, BOK, BIK, BAD, BID, PUMA
(also known as BBC3) and BMF increased by 450% in
TTC5 KD cells by comparison with control cells at one or the
other time point (Figure 4a). The change in expression of
other genes was less marked. Reduced BCL2 expression
was confirmed in repeat experiments with two separate
TTC5 KD constructs at both protein (Figure 4b) and
transcript levels (Figures 4c and d). To determine whether
reduced expression of BCL2 contributes to apoptosis of AML
cells following TTC5 KD, we force-expressed BCL2 in THP1
cells and repeated KD. Interestingly, we observed an
increase in both BCL2 transcripts and protein in BCL2-
overexpressing THP1 cells following TTC5 KD (Figures 4b
and d), suggesting that TTC5 may directly or indirectly
contribute to repression of the integrated retroviral long
terminal repeat promoter. Forced expression of BCL2
(Figures 4b–d) blocked apoptosis and partially rescued the
loss of clonogenic potential consequent upon TTC5
KD (Figures 4e and f). However, forced expression of
BCL2 did not rescue the modest but significant G1 arrest
and reduction of the proportion of cells in S phase, likely
explaining why only a partial rescue was observed
(Figure 4g). Thus, TTC5 selectively and positively regu-
lates expression of BCL2 in human AML cells, either
directly or indirectly, and downregulation of BCL2 following
TTC5 KD contributes to apoptosis and loss of clonogenic
potential.
EP300 sustains the expression of BCL2 in AML cells.
TTC5 was originally identified in complex with EP300 and
an EP300-interacting protein JMY,3 and was also found to
augment EP300 histone acetyltransferase activity in
U2OS osteosarcoma cells.6 We therefore hypothesized
that TTC5 might similarly regulate EP300 activity in human
THP1 AML cells to enhance cell survival. Consistent
with this, EP300 KD to 51±8% (mean±S.E.M.; n¼ 3) of
control levels induced a similar phenotype to TTC5 KD:
EP300 KD cells exhibited reduced BCL2 expression (Figures
5a and b), a 450% increase in expression of the pro-
apoptotic genes BID, PUMA and BMF (which were also
induced by TTC5 KD) (Figure 5c), and a failure to form
colonies in semisolid culture (Figure 5d) due to induction of
apoptosis (Figure 5e). These data suggest that TTC5 and
EP300 cooperate, directly or indirectly, to maintain expres-
sion of BCL2 in AML cells and repress pro-apoptotic genes
such as BID, PUMA and BMF, thus preventing leukemia cell
apoptosis.
Figure 3 Ttc5 is required to maintain the leukemia-initiating potential of murine MLL-AF9 AML cells. MLL-AF9 cells were infected with lentiviruses expressing shRNAs
targeting Ttc5 for KD or a non-targeting control (NTC) shRNA, with GFP as the selectable marker. After 48 h, cells were FACS-purified for GFP expression. Bar charts show
(a) mean±S.E.M. CFC frequencies of control and Ttc5 KD cells after 5 days in semisolid culture (n¼ 3) and (b) mean±S.E.M. Ttc5 mRNA levels in KD cells relative to
control cells 48 h following lentiviral infection (n¼ 3). (c) Survival curves of sublethally irradiated syngeneic mice secondarily transplanted with 1000 control or Ttc5 KD AML
cells (n¼ 4 mice per cohort). (d) Representative FACS plots show the presence of GFPþ donor AML cells in the BM of a leukemic mouse transplanted with control cells (Day
60) and absence of AML cells in a mouse transplanted with Ttc5 KD cells at termination of the experiment (Day 120). * Indicates Pp0.05 for comparison of KD versus control
conditions using one-way ANOVA and Fisher’s least significant difference post hoc test
TTC5 mediates cell survival in AML
JT Lynch et al
4
Cell Death and Disease
TTC5 and EP300 regulate turnover of MYC in AML cells.
The pattern of change in expression of BCL2 family genes
following TTC5 KD (Figure 4a), with reduced expression of
BCL2 and increased expression of pro-apoptotic genes, was
reminiscent of the pattern we have previously observed in
AML cells in which Myc was force-expressed (Huang et al,
2013, manuscript submitted). Furthermore, EP300 regulates
the stability of MYC through both acetylation-dependent
and acetylation-independent mechanisms.11 These data
prompted us to investigate whether TTC5 or EP300 KD
altered the expression of MYC. Neither TTC5 KD nor EP300
KD in THP1 AML cells led to a significant change in the
expression of MYC transcripts (Figures 6a and b). By
contrast, both TTC5 KD and EP300 KD led to a robust
accumulation of MYC protein (Figure 6c), which was
explained by an increase in its cellular half-life fromo30min
(control cells) to 460min (EP300 KD) (Figures 6d and e).
Given that EP300 directly acetylates MYC at K148, K157 and
K323,11 we next investigated whether acetylation of MYC at
these residues was perturbed in TTC5 or EP300 KD cells.
In contrast to the robust accumulation of total MYC
protein, levels of acetyl-K157 MYC did not change following
either TTC5 or EP300 KD, and levels of acetyl-K148
MYC increased only modestly (Figure 7a); this was
confirmed by semiquantitative assessment of western blot
bands using ImageJ analysis (Figure 7b). By contrast,
acetylation of MYC at K323 was not readily detected in
control or TTC5 KD THP1 cells, although it was detected in
EP300 KD cells. Thus, following TTC5 or EP300 KD, the
form of MYC that accumulated in human AML cells is
relatively hypoacetylated at K148 and K157. These data are
consistent with previously described roles for EP300 in MYC
Figure 4 TTC5 prevents apoptosis of THP1 cells through regulation of BCL2 expression. THP1 cells were infected with lentiviruses expressing shRNAs targeting TTC5 for
KD, or a non-targeting control (NTC) shRNA, with puromycin drug resistance as the selectable marker. Bar chart shows (a) mean±S.E.M. transcript expression levels of the
indicated genes in KD cells relative to control cells at the indicated time points following lentiviral infection (n¼ 2). (b) Representative western blots show expression of the
indicated proteins, 7 days after lentiviral infection. Bar charts show (c) mean±S.E.M. TTC5 or (d) BCL2 transcript levels in control (EV, empty vector) or BCL2 overexpressing
TTC5 KD THP1 cells relative to control cells, 72 h after lentiviral infection (n¼ 3). Bar charts show (e) mean±S.E.M. percentage of apoptotic cells, as determined by annexin
V binding, 7 days after lentiviral infection (n¼ 3) and (f) mean±S.E.M. colony-forming cell (CFC) frequencies of drug-resistant cells enumerated following 10 days in semisolid
culture (n¼ 3). * Indicates Pp0.05 (Mann–Whitney U-test) for comparison of KD versus control conditions, or for the indicated comparisons. NS¼ not significant. (g) Bar
chart shows mean±S.E.M. percentage of TTC5 KD cells in G1 or S phase of cell cycle relative to that observed in control cells (for BCL2 over expressing and control THP1
lines) 96 h after initiation of KD (n¼ 3). * Indicates Pp0.05 for comparison of KD versus control conditions using one-way ANOVA and Fisher’s least significant difference post
hoc test
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acetylation and turnover11 and TTC5 in regulation of the HAT
activity of EP300.3,6
To determine whether TTC5 and MYC interact,
co-immunoprecipitation experiments were performed in
293FT cells: an HA-tagged version of TTC5 readily pulled
down co-expressed MYC in (Figure 7c). Finally, to determine
whether MYC accumulation might contribute to induction of
apoptosis, we performed TTC5 KD in THP1 cells where
murine Myc was force-expressed. Expression of murine Myc
transcripts was detected in Myc-expressing human THP1
cells, but was absent in control cells (data not shown).
Consistent with a role for MYC in sensitizing cells to
apoptosis,12 THP1 cells force-expressing Myc exhibited
significantly greater levels of apoptosis by comparison with
control cells, both when infected with non-targeting control
vectors (albeit modestly) and when infected with vectors
targeting TTC5 for KD (Figures 7d and e). The substantially
greater proportion of TTC5 KD versus control cells under-
going apoptosis in the context of Myc forced expression
furthermore suggested a quantitative link between the amount
of cellular MYC and the rapidity of onset of apoptosis. There
was no significant difference in the clonogenic potential of
control or Myc force-expressing TTC5 KD cells (Figure 7f).
Together, these data indicate a role for TTC5 in the regulation
of MYC protein turnover in leukemia cells and suggest that
MYC accumulation might contribute to the induction of
apoptosis through altering the balance of expression of anti-
versus pro-apoptotic proteins.
Discussion
TTC5 was originally described as an EP300-interacting
transcription cofactor that accumulates following etoposide
treatment of U2OS osteosarcoma cells, and which augments
the TP53 response.3 Subsequent work has identified more
general roles for TTC5 in the regulation of the cellular
response to stress, for example, following heat shock.6 Our
studies using cells from two different species now reveal roles
for TTC5 in the prevention of apoptosis of leukemia cells and
maintenance of their clonogenic capacity, through regulation
of MYC and BCL2 expression. Syngeneic and xenogeneic
transplantation experiments confirm an in vivo requirement for
TTC5 in leukemia initiation, as well as its in vitro requirement.
Importantly, our observations are not explained by an effect
on TP53 because THP1 cells exhibit a frame-shift deletion of
TP53 from R17413 and, as expected, we were unable to
detect TP53 expression in these cells (data not shown). While
the dependency of AML cells on TTC5 was discovered in
the context of the MLL mutated molecular subtype of AML,
the in vitro clonogenic activity of AML cell lines representative
of other molecular subtypes was likewise dependent on
TTC5, suggesting a wide role for the protein in leukemic
hematopoiesis.
Knockdown of either TTC5 or EP300 in AML cells similarly
alters the balance of expression of pro- versus anti-apoptotic
genes, consistent with the physical and functional interaction
of their gene products. The decrease in expression of the anti-
apoptotic gene BCL2 and increase in expression of pro-
apoptotic genes such asBID,PUMA andBMF likely alters the
cellular apoptotic rheostat in favor of apoptosis. Such changes
might be explained by localized, specific and direct effects of
a TTC5/EP300 complex at gene promoters to repress or
activate expression respectively. Alternatively, changes in
gene expression might be consequent upon altered expres-
sion of a protein target of the histone acetyltransferase activity
of the TTC5/EP300 complex.
In support of the latter interpretation, we have previously
found that forced expression of Myc in AML cells induces
expression of pro-apoptotic genes (Huang et al, 2013,
manuscript submitted). In contrast, forced expression of
Myc in THP1 cells reduces expression of BCL2 relative to
ACTB to 44±12% of control levels (mean±S.E.M., n¼ 3).
The similarity in the change in expression of pro- versus
Figure 5 EP300 KD phenocopies TTC5 KD. THP1 cells were infected with
lentiviruses expressing shRNAs targeting EP300 for KD, or a non-targeting control
shRNA (NTC), with puromycin drug resistance as the selectable marker. (a) Bar
chart shows mean±S.E.M. BCL2 mRNA levels in EP300 KD cells relative to
control cells, 72 h after lentiviral infection (n¼ 3). (b) Representative western blot
shows expression of the indicated proteins, 72 h after lentiviral infection (n¼ 3).
(c) Bar chart shows mean±S.E.M. transcript levels of the indicated genes in EP300
KD cells relative to control cells, 72 h after lentiviral infection (n¼ 3). Bar charts
show (d) mean±S.E.M. colony-forming cell (CFC) frequencies of drug-resistant
cells enumerated following 10 days in semisolid culture (n¼ 3) and
(e) mean±S.E.M. percentage of apoptotic cells, as determined by annexin V
binding, 7 days after lentiviral infection (n¼ 3). * indicates Pp0.05 (Mann–Whitney
U-test) for comparison of KD versus control conditions
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Figure 6 TTC5 and EP300 promote MYC turnover. THP1 cells were infected with lentiviruses expressing shRNAs targeting TTC5 or EP300 for KD, or a non-targeting
control shRNA (NTC), with puromycin drug resistance as the selectable marker. Bar charts show (a) mean±S.E.M. mRNA levels of MYC and TTC5 in TTC5 KD cells and
(b) mean±S.E.M. mRNA levels of MYC and EP300 in EP300 KD cells relative to control cells, 72 h after lentiviral infection (n¼ 3). Representative western blots show
(c) expression of MYC after EP300 or TTC5 KD (n¼ 3) and (d) MYC half-life, as determined by incubation of control or KD cells with 10 mg/ml cycloheximide for the indicated
times, 72 h after lentiviral infection (n¼ 2). Vertical dashed line demarcates separate gels, although exposure time was identical. (e) MYC half-life was semiquantified by
densitometric analysis using ImageJ software
Figure 7 Myc accumulation and apoptosis after TTC5 or EP300 KD. THP1 cells were infected with lentiviruses expressing shRNAs targeting TTC5 or EP300 for KD, or a
non-targeting control shRNA (NTC), with puromycin drug resistance as the selectable marker. (a) Representative western blots show expression of MYC, acetylated MYC and
ACTB after EP300 or TTC5 KD, 72 h after lentiviral infection. (b) Bar chart shows semiquantitative analysis of acetyl-K148 MYC or acetyl-K157 MYC signal as a percentage of
total MYC signal, as determined by ImageJ analysis of the bands shown in (a). (c) 293FT cells were transiently transfected with the indicated constructs. After 48 h, cells were
harvested and lysates were immunoprecipitated with an HA-tag antibody. The immunoprecipitated complex was analyzed by western blotting using MYC or TTC5 antibodies.
IP¼ immunoprecipitation. (d–f) Control andMyc-overexpressing THP1 cells were infected with lentiviruses expressing shRNAs targeting TTC5 for KD or a NTC shRNA, with
puromycin drug resistance as the selectable marker. (d) Representative FACS plots show annexin V and 7-aminoactinomycin (7-AAD) binding to control and KD cells, 7 days
after lentiviral infection. Bar charts show (e) mean±S.E.M. percentage of apoptotic cells, as determined by annexin V binding, 7 days after lentiviral infection (n¼ 3); and
(f) mean±S.E.M. colony-forming cell (CFC) frequencies of drug-resistant cells enumerated following 10 days in semisolid culture (n¼ 3). EV¼ empty vector. * indicates
Pp0.05 (paired t-test) for comparison of KD versus control conditions
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anti-apoptotic genes observed following Myc-overexpression
or TTC5/EP300 KD prompted our investigation of MYC as an
intermediary of the observed gene expression changes. MYC
associates directly with and is acetylated by EP300 on
multiple residues, including K148, K157 and K323.11 Acety-
lation of MYC by EP300 promotes its turnover.11 In keeping
with these observations, we observed that EP300 KD led to
robust accumulation of a form of MYC that was relatively
hypoacetylated at both K148 and K157; TTC5KD gave similar
results. Together, these data support a role for TTC5 in
promoting the turnover of MYC though its regulation of the
acetyltransferase activity of EP300. Given that TPR-motif
proteins function as scaffolding proteins, it is possible that
TTC5 could stabilize the interaction between EP300 and
MYC.14
While physiologic levels of MYC are required for normal cell
cycle progression, accumulation of MYC above a certain
threshold is associated with induction of apoptosis,12 through
a transcriptionalmechanism that results in leak of cytochrome c
from the mitochondrion into the cytoplasm.15 We found a
modest but significant increase in apoptosis in THP1 cells
whereMycwas force-expressed. However, following TTC5 or
EP300 KD, the extent of apoptosis was much greater,
consistent with the observed significant and substantial
accumulation of endogenous MYC. Nevertheless, our obser-
vations of a role for TTC5 in the regulation of MYC turnover do
not rule out other important roles for TTC5 in leukemic
hematopoiesis. For example, because TTC5 is an EP300-
interacting protein, and given the varied and critical roles of
EP300 in hematopoiesis, it is possible that TTC5 regulates
other hematopoietic transcriptional complexes.16,17
Materials and Methods
Cell lines, culture and clonogenic assays. THP1 and MonoMac-1
cells were from DMSZ (Braunschweig, Germany). MV(4;11), NB4, HL60 and K562
cells were gifts from Dr. Vaskar Saha and were cultured as recommended
(www.dmsz.de). Clonogenic assays of cell lines were performed in methylcellulose
medium (H4320, Stem Cell Technologies, Vancouver, BC, Canada) with no
supplemental growth factors. Liquid culture of murine AML cells was in RPMI 1640
containing 20% fetal calf serum and 5% X63 supernatant.18 Clonogenic assays of
murine AML cells were performed in methylcellulose medium (M3231, Stem Cell
Technologies) containing 20 ng/ml SCF, 10 ng/ml IL6, 10 ng/ml GM-CSF and
10 ng/ml IL3 (Peprotech, London, UK).
Table 1 Primer and probe sets used for Q-PCR
Gene Q-PCR primer sequences Roche probe library number
TTC5 F ACCGAATTCAGCACAAAGGA 47
TTC5 R CTAGCAGGAGGGGCGTCT —
ACTB F ATTGGCAATGAGCGGTTC 11
ACTB R GGATGCCACAGGACTCCAT —
EP300 F GATCTGTGTCCTTCACCATGAG 40
EP300 R AAACAGCCATCACAGACGAA —
MYC F GCTGCTTAGACGCTGGATTT 66
MYC R TAACGTTGAGGGGCATCG —
BCL2 F AGTACCTGAACCGGCACCT 75
BCL2 R GCCGTACAGTTCCACAAAGG —
BCL2L1 (BCL-XL) F AGCCTTGGATCCAGGAGAA 66
BCL2L1 (BCL-XL) R AGCGGTTGAAGCGTTCCT —
MCL1 F TGGATGGTGGCCTACCTG 28
MCL1 R CGTCCCCGTATAGAGCTGT —
BCL2A1 (A1) F CAGGAGAATGGATAAGGCAAA 75
BCL2A1 (A1) R CCAGCCAGATTTAGGTTCAAA —
BCL2L2 (BCL-W) F TGGATGGTGGCCTACCTG 28
BCL2L2 (BCL-W) R CGTCCCCGTATAGAGCTGTG —
BAX F AGCAAACTGGTGCTCAAGG 69
BAX R TCTTGGATCCAGCCCAAC —
BAK F TGGTCACCTTACCTCTGCAAC 43
BAK R ATGTCGTCCCCGATGATG —
BIK F CCCTATGGAGGACTTCGATTC 28
BIK R GGCTCACGTCCATCTCGT —
BCL2L11 (BIM) F CATCGCGGTATTCGGTTC 70
BCL2L11 (BIM) R GCTTTGCCATTTGGTCTTTTT —
BAD F CGAGTTTGTGGACTCCTTTAAGA 78
BAD R CACCAGGACTGGAAGACTCG —
BID F GTGCTGGGGTCATGATGG 19
BID R CGACTCACTCCTGGTTCACA —
BBC3 (PUMA) F GACCTCAACGCACAGTACGA 51
BBC3 (PUMA) R CACCTAATTGGGCTCCATCTC —
PMAIP1 (NOXA) F GGAGATGCCTGGGAAGAAG 67
PMAIP1 (NOXA) R CCTGAGTTGAGTAGCACACTCG —
BMF F GAGACTCTCTCCTGGAGTCACC 25
BMF R CTGGTTGGAACACATCATCCT —
Ttc5 F TGCAGCAGATGGAGGAAGTA 98
Ttc5 R GAGTCACATTCAGTGCCTTCC —
Actb F TGACAGGATGCAGAAGGAGA 106
Actb R CGCTCAGGAGGAGCAATG —
Myc F CCTAGTGCTGCATGAGGAGA 77
Myc R TCCACAGACACCACATCAATTT —
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Reagents, plasmids and lentiviral production. Puromycin, cyclo-
heximide and lentiviral vectors were purchased from Sigma (Poole, UK). Vectors
were as follows: non-targeting control pLKO.1 (SHC002); TTC5 KD pLKO.1
(TRCN0000156809 (#1), TRCN0000156289 (#2) and TRCN0000152678 (#4));
Ttc5 KD pLKO.1 (TRCN0000176549 (#1), TRCN0000178101 (#2) and
TRCN0000181231 (#3)) and EP300 KD pLKO.1 (TRCN0000039886). For the
murine Ttc5 KD constructs, the PGK-puromycin cassette was exchanged for an
SFFV-eGFP cassette (amplified from pHR0SIN.cPPT-SEW, a gift from Dr. Adrian
Thrasher), to generate eGFP versions. To generate a lentiviral vector for
expression of TTC5, TTC5 cDNA was PCR amplified using pcDNA3-HA-TTC5 as
a template (a gift from Marija Krstic-Demonocas), incorporating Cla1 and Xba1
restriction sites, using the following primers:
 50 ATAATATCGATATGATGGCTGATGAAGAGGAAGAAGTC,
 30ATAATTCTAGATCATTCACACTGTGGTCGCGATG.
The amplified fragment was sequence-verified and cloned in to the Cla1 and Xba1
sites of pLentiGS downstream of an EF1a promoter (Huang et al, 2013, manuscript
submitted). pMSCV-BCL2-IRES-GFP (#8972) and pMSCV-Myc-IRES-GFP (#18770)
were purchased from Addgene (Cambridge, MA, USA). Lentiviral and retroviral
supernatants were prepared and leukemic human and murine cells infected with viral
particles as described.19
Western blotting and immunoprecipitation. For western blotting, cells
were lysed in High Salt Lysis Buffer (45mM HEPES (pH 7.5), 400mM NaCl, 1 mM
EDTA, 10% Glycerol, 0.5% NP40, 6.25mM NaF, 20mM b-glycerophosphate,
1mM DTT, 20mM sodium butyrate and 1 Protease Inhibitor cocktail (Roche,
Burgess Hill, UK)) and equal amounts of protein were loaded and separated by
SDS-PAGE. For co-immunoprecipitation, cells were lysed in NP40 Lysis Buffer
(50mM Tris/HCl (pH 8.0), 50 mM KCl, 10mM EDTA, 1% NP40, 6.25mM NaF,
20mM b-glycerophosphate, 1 mM DTT and 1 Protease Inhibitor cocktail
(Roche)). Lysate was incubated overnight with the appropriate antibody and
immune complexes were pulled down with Protein G–Sepharose (Sigma).
Samples were washed four times with IP wash buffer (50mM Tris/HCl (pH 7.5),
150mM NaCl, 5 mM EDTA and 0.1% Tween 20), eluted and separated by SDS-
PAGE. Horseradish peroxidase-linked secondary antibodies (GE Healthcare, Little
Chalfont, UK) and ECL (enhanced chemiluminescence; GE Healthcare) or
Supersignal (Pierce, Rockford, IL, USA) were used to detect immune complexes.
Protein expression levels were quantified using ImageJ software (NIH, USA).
Antibodies used for western blotting or immunoprecipitations were as follows: anti-
TTC5 (PAB12888, Abnova, Cambridge, UK), anti-ACTB (C4, Millipore, Watford,
UK), anti-BCL2 (#124, Dako, Ely, UK), anti-MYC (Y69, Abcam, Cambridge, UK),
anti-acetyl MYC K148 (ABE25, Millipore), anti-acetyl MYC K157 (ABE27,
Millipore), anti-acetyl MYC K323 (ABE26, Millipore) and anti-HA (12CA5, Abcam).
RNA isolation and analysis. RNA was extracted using QIAshredder spin
columns and an RNeasy Plus Micro kit (Qiagen, Manchester, UK). For quantitative
PCR, first strand synthesis was performed using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Paisley, UK). Quantitative PCR assays
were performed in 384-well MicroAmp optical reaction plates using Taqman Fast
Universal PCR Mastermix (Applied Biosystems) and Universal Probe
Library System (Roche) designed primers and probes, which are listed in Table 1.
Flow cytometry, apoptosis and cell cycle analysis. FACS analyses
were performed using a LSR Model II flow cytometer (BD Biosciences, Oxford, UK).
Cell sorting experiments were performed using either an Influx or a FACSAria II
flow cytometer (both from BD Biosciences). Anti-CD45-PE-Cy7 (HI30) was from
eBioscience (Hatfield, UK). Apoptosis was assessed using a BD Pharmingen APC
Annexin V Kit (Oxford, UK), according to the manufacturer’s instructions.
Propidium iodide cell cycle analyses were performed as described.20
Mice and murine experiments. Experiments were approved by the
Paterson Institute’s Animal Ethics Committee and performed under a project
license issued by the United Kingdom Home Office, in keeping with the Home
Office Animal Scientific Procedures Act, 1986. C57BL/6 (CD45.2þ ) mice were
purchased from Harlan (Shardlow, UK). NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and bred
in-house. The cohort of mice with syngeneic MLL-AF9 AML, initiated using a
retroviral transduction and transplantation protocol, was generated as
described.10,19
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